Freedom of information (FOI) releases from OUH

This is a disclosure log of Oxford University Hospitals NHS Foundation Trust's responses to freedom of information (FOI) or environmental information regulations (EIR) requests that might be of wider public interest.

If you can't find the information you're looking for, you can make a new FOI request.

Filters

Clear filters
  • Keywords filters

  • Year filters

  • Month filters

211 disclosures

  1. I am requesting information relating to the procurement and use of intraosseous (IO) access devices within your Trust. Specifically, I request the following information for the most recent full financial year for which data is available (please state the year in your response):


    1. INTRAOSSEOUS DEVICE USAGE - GENERAL
    a) Does your Trust currently use intraosseous access devices? (Yes/No)
    b) Which intraosseous device(s) are in current use across the Trust? Please include the product name, manufacturer, and model.

    c) What is the total number of intraosseous needles/sets consumed per year across all clinical departments and settings?
    d) What is the total annual expenditure on intraosseous needles and consumables?

    2. EZ-IO SYSTEM (TELEFLEX / VIDACARE)
    a) Does your Trust use the EZ-IO intraosseous infusion system? (Yes/No)
    b) If yes, how many EZ-IO powered drivers (handsets) are currently held within the Trust?
    c) What was the capital expenditure on EZ-IO drivers in the most recent full financial year?
    d) How many EZ-IO needles were consumed in the most recent full financial year? Please break this down by needle gauge/size if possible (e.g. 15mm, 25mm, 45mm).

    e) What was the total annual expenditure on EZ-IO needles?
    f) Under what procurement route were the EZ-IO products sourced (e.g. NHS Supply Chain, direct contract, framework agreement)?


    3. CONTRACT AND PROCUREMENT INFORMATION
    a) Is intraosseous device procurement covered by a current contract or framework? If so, please state the contract name, reference number, and expiry date.
    b) When is this contract next due for renewal or retender?

    Published: 22 October 2026

  2. Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

     Name of medicine 

     

    Number patients treated 

    1.1 Abiraterone (Zytiga or generic abiraterone) 

     

     

    1.2 Apalutamide (Erleada) 

     

     

    1.3 Cabazitaxel

     

     

    1.4 Darolutamide (Nubeqa) 

     

     

    1.5 Docetaxel  

     

     

    1.6 Enzalutamide (Xtandi) 

     

     

    1.7 Lutetium-177 PSMA-617 (Pluvicto)

    1.8 Olaparib (Lynparza) 

     

     

    1.9 Relugolix (Orgovyx, Ryeqo) 

     

     

    1.10 Talazoparib (Talzenna)  

     

     

     

    Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

     Name of medicine 

     

    Number patients treated 

    2.1 Docetaxel for prostate cancer 

     

     

    2.2 Olaparib (Lynparza) for prostate cancer 

     

     

    2.3 Talazoparib (Talzenna) for prostate cancer 

     

     

    2.4 Relugolix (Orgovyx) for prostate cancer 

     

     

     

    Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st April 2026 to the end of June 2026, or latest 3-months for which data are available? 

     Name of medicine 

     

    Number patients treated in Cycle 1 or Dose 1 

    3.1 Abiraterone (Zytiga or generic abiraterone) 

     

     

    3.2 Apalutamide (Erleada) 

     

     

    3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 

     

     

    3.4 Darolutamide (Nubeqa) 

     

     

    3.5 Enzalutamide (Xtandi) 

     

     

     

    Q4. How many patients were treated with the following combinations in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?  Please give total number of patients and number of patients receiving their first dose or first cycle. 

     Name of medicine 

     

    Total Number patients treated 

     

    Number patients received cycle 1 or dose 1 

    4.1 Darolutamide (Nubeqa) + Docetaxel  

     

     

     

     

    4.2 Darolutamide (Nubeqa) monotherapy

     

     

     

     

    4.3 Olaparib (Lynparza) + Abiraterone 

     

     

     

     

     

    Q5. How many patients were switched from the following products to darolutamide (Nubeqa) in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available?

     Name of medicine 

     

    Number patients switched

    5.1 Abiraterone  

     

     

    5.2 Apalutamide

     

     

    5.3 Enzalutamide

     

    Q6. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

     Name of medicine 

     

    Number patients treated 

    6.1 Abiraterone  

     

     

    6.2 Enzalutamide 

     

     

     

    Q7. How many patients were treated with darolutamide (Nubeqa) for the following indications and BlueTeq CDF codes between July 2026 to the end of September 2026? 

    BlueTeq CDF code 

    BlueTeq CDF description (copied from CDF List) 

    Number of patients 

    DARO1

    Darolutamide for non-metastatic hormone-resistant (castration-resistant) prostate cancer

    DARO2

    Darolutamide in combination with docetaxel and ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer

    DARO3

    Darolutamide in combination with ADT for patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel

     

     

    Q8. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

    Product

     

    Number patients treated 

    8.1 Cemiplimab (Libtayo) for Non-small Cell Lung Cancer

     

     

     

    Q9. How many patients received Cemiplimab (Libtayo) for Non-small Cell Lung Cancer in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

     Combination or monotherapy for Non-small Cell Lung Cancer

     

    Number patients treated 

    9.1 Cemiplimab + Cisplatin or Carboplatin chemotherapy

     

     

    9.2 Cemiplimab monotherapy

     

     

     

    Q10. How many patients received the following products in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

     Product

     

    Number patients treated 

    10.1 Amivantamab (Rybrevant)

     

     

    10.2 Lazertinib (Lazcluze)

    10.3 Osimertinib (Tagrisso)

     

     

     

    Q11. How many patients received the following products in combination or as monotherapy in the 3 months between July 2026 to the end of September 2026? 

     Product

     

    Number patients treated 

    11.1 Amivantamab + Lazertinib

     

     

    11.2 Amivantamab + Carboplatin + Pemetrexed

    11.3 Amivantamab Monotherapy

    11.4 Osimertinib + Pemetrexed + Platinum Chemotherapy

     

     

    11.5 Osimertinib Monotherapy

     

    Q12. How many patients received Osimertinib (Tagrisso) as Adjuvant treatment in the 3 months between July 2026 to the end of September 2026, or latest 3-months for which data are available? 

    Product

     

    Number patients treated 

    12.1 Osimertinib as adjuvant treatment

     

    Published: 21 October 2026

  3. 1. What is the total number of Electrosurgical Units (ESUs) that offer all modalities (monopolar, bipolar, advanced energy & ultrasonic) in the hospital?

    2. What electrosurgical units (ESUs) does the hospital have that offer all modalities (monopolar, bipolar & advanced energy)?


    3. Are the ESUs loaned or owned? If loaned, is it linked to consumable purchase/contract? If owned, when will there be upgrades?

    4. Does the hospital do ERBE in Endoscopy?

    5. What accessories came with the generators?

    6. Does the hospital have dedicated smoke evacuation units? If so, how many units and what brand?


    7. Can the smoke evacuation unit work on all ESUs or only specific ones?

    Published: 20 October 2026

  4. I am writing on behalf of Little Ripples, a charity working to improve emotional wellbeing and support for children and young people affected by a family member's cancer diagnosis. Little Ripples (Registered Charity No. 1218526) is building the evidence base for future work on this issue.

    Our interest in this area began with the experience of families who found that support for children after a cancer diagnosis varied significantly depending on where they were treated. Some received timely Holistic Needs Assessments and clear referral pathways for their children. Others did not. We want to
    understand how widespread this variation is, and to use that evidence to support NHS trusts, Cancer Alliances and policymakers in closing the gap.

    Our questions are as follows.

    Section I: Holistic Needs Assessment (HNA)

    1.Does your Trust have a written policy, guideline or standard operating procedure describing when a Holistic Needs Assessment (HNA) should first be offered to adult cancer patients following
    diagnosis, including any specific target timeframe? If yes, please provide a copy or link to the document, and state the target timeframe if one is specified.


    2. Is the timing of the first HNA monitored through any local quality standard, performance indicator or audit? If yes, please provide the relevant documentation or description.


    3.Is the offer or completion of HNAs monitored, recorded, or reported against any equality characteristic (for example ethnicity, disability, or deprivation) or against patients' first language? If yes and readily available, please provide the relevant documentation. If no, please confirm this.

    Section II: Supporting Children and Families

    4. Does your Trust have any written policy, guidance or assessment process requiring healthcare professionals to identify whether an adult cancer patient has dependent children (under 18 years of
    age)? Please provide copies where available.


    5. Where dependent children are identified, does your Trust have a documented pathway or protocol describing what information, advice or support should be offered to the patient and their family? Please provide copies where available.

    6. Does your Trust provide any written information, leaflets, webpages or digital resources specifically intended to help parents diagnosed with cancer communicate with or support their
    children? Please provide copies or web links.

    7. Are the materials referred to in question 6 available in accessible formats (for example easy read or large print) or in languages other than English? If yes, please list which formats or languages,
    where this is readily available. If no, please confirm this.


    Section III: Referral Pathways

    8. Does your Trust have formal referral arrangements for patients with dependent children to any of the following? Please indicate Yes/No for each, and provide the relevant pathway or protocol if
    documented.
    a) Psychological support –
    b) Social work -
    c) Family support services -
    d) Children's services -
    e) Voluntary sector organisations -
    f) Other (please specify)

    9. Does your Trust work with any external charities or voluntary organisations that provide support to children affected by a parent's cancer? If yes, please identify the organisations.


    Section IV: Workforce

    10. Are healthcare professionals involved in delivering HNAs provided with any guidance or training relating specifically to supporting patients with dependent children? If yes and centrally held, please provide the training materials or guidance.

    Section V: Quality Improvement

    11. Has your Trust undertaken any audit, evaluation, quality improvement project or service review since April 2024 relating to Holistic Needs Assessments or support for dependent children of adult cancer patients? If yes, please provide copies of any published reports or summaries.


    Section VI: Governance and Engagement

    12. Who within your Trust has executive or clinical responsibility for overseeing personalised cancer care and Holistic Needs Assessments? Please provide the job title(s) rather than personal names where appropriate.

    Published: 20 October 2026

  5. Under the Freedom of Information Act 2000, we are requesting information regarding the provision of adult sleep apnoea diagnostic and treatment services at your organisation.

    For the purposes of this request, "sleep apnoea services" refers to services for the diagnosis and treatment of obstructive sleep apnoea and related sleep-disordered breathing conditions in adults.
     
    Question 1. Does your organisation provide a sleep apnoea diagnostic and treatment service?
    a. Yes
    b. No


    Question 2 Please identify the commissioner(s) funding the service.
    For each commissioner, please provide:
    a. Commissioner name
    b. Contract start date
    c. Contract end date (or indicate if open-ended)
     


    Question 3 What payment mechanism applies to the service?
     
    Please provide the description used within the relevant contract or service agreement.
     
    Question 4
    What was the income received by your organisation from sleep apnoea services during the most recent completed financial year for which data are available? 
    If this information is not separately recorded, please state this. 
     
    Question 5
    Does your organisation deliver the service: 
    a. Directly using employed staff;
    b. Through a subcontracted or outsourced provider arrangement;
    c. Through a partnership arrangement with another NHS provider; or
    d. Through another model (please specify).

    Published: 20 October 2026

  6. 1. Your definition of an active case of influenza.

    2. The methods used to confirm an influenza case and distinguish it from other acute respiratory infections.

    Published: 20 October 2026

  7. 1. A recent response includes the statement - the Trust oversees the contract and receives high‑level assurance information - please can you provide information on the manner in which the contract is overseen and what high level assurance is received. This should at the very least cover evidence of compliance with NHS Car Parking Guidance 2022


    2. Please can you state how many formal and informal complaints (PALS) enquiries you have received relating to parking at any of your sites for the last 2 years.



    3. Please can you advise how many of the above resulted in the cancellation of PCNs.



    4. A parking contract with an external provider allows a non NHS provider to come onto your site and obtain registration details for vehicles belonging to patients and their families. The KADOE contract with the DVLA then allows the contractor to obtain names and addresses of the legal keepers of the vehicles. This means you are facilitating a third party to obtain highly sensitive data (hospital attendance) over which you apparently have no control. Please can you provide a copy of the mandatory Privacy Impact Assessment that was completed and risk assessed before the latest contract for car parking was agreed. I am particularly interested in any discussion relating for the potential for third parties to be made aware of someone's attendance at a health facility without their consent.

     

    Published: 20 October 2026

  8. I would like to know how many appointments for dermatology were provided by the Trust in the months of March 26, April 26 and May 26 and of these appointments, how many were provided to non-British citizens or persons with refugee / asylum status at the time of the appointment.

    Published: 19 October 2026

  9. Q1 Please provide your evaluation of your Trust's winter plan for 2025-2026

    Q2 Please provide your winter plan for 2026-2027

    Published: 19 October 2026

  10. I understand that the parking was overtake last year by a different parking company from SIPcarparks.

    Please can you tell me the following:
    1. When the signage was updated in the west wing car parks and associated areas

    2. When the ticket machine was replaced in the underground parking section at the west wing?

    Published: 16 October 2026